source
- Retifanlimab plus chemo improves progression-free survival in first-line SCAC trialTopline results from the PODIUM-303 study show that adding the PD-1 inhibitor retifanlimab to carboplatin and paclitaxel improves outcomes for patients with squamous cell carcinoma of the anal cana…
- MD Anderson expert highlights impact of WHO’s updated AML diagnostic criteria on patient careDr Sanam Loghavi, an associate professor and medical director at MD Anderson Cancer Center, discussed the recently revised WHO diagnostic criteria for acute myeloid leukemia. She emphasized that a…